GlassScriptPhysician profile
Kimberly An Ho
NPI 1053801670
$16,736.99
in general payments reported to CMS, 2019-2025
61 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $4,648 · 2023: $5,181 · 2024: $6,162 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,491 · Long Term Medical Supply Or Device Loan: $1,232 · Education: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,491.42 |
| Long Term Medical Supply Or Device Loan | $1,232.10 |
| Education | $725.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,534.09 | 2021-2024 | |
| Celgene Corporation | $1,183.86 | 2022-2024 | Reblozyl, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $997.84 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $949.64 | 2021-2025 | Xospata, Padcev, Xtandi |
| Pfizer INC. | $882.28 | 2021-2024 | |
| Incyte Corporation | $800.78 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $715.53 | 2022-2024 | Opdivo |
| Eisai INC. | $597.03 | 2021-2024 | |
| Janssen Biotech, INC. | $572.30 | 2022-2024 | Erleada, Imbruvica, Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $568.23 | 2022-2024 | Ninlaro, Iclusig, Fruzaqla |
| Exelixis INC. | $472.74 | 2021-2024 | Cabometyx |
| Glaxosmithkline, LLC. | $446.37 | 2021-2024 | Zejula, Jemperli, Ojjaara |
| Lilly USA, LLC | $393.54 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $345.84 | 2022-2024 | |
| Daiichi Sankyo INC. | $322.73 | 2021-2024 | Enhertu |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $315.37 | 2022-2024 | Enhertu, Lynparza, Tagrisso |
| Abbvie INC. | $310.16 | 2023-2025 | |
| Genzyme Corporation | $254.02 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.86 | 2021-2024 | Gilotrif |
| Taiho Oncology, INC. | $228.55 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $216.50 | 2022-2024 | Xpovio |
| Beigene USA, INC. | $181.60 | 2022-2024 | Brukinsa |
| Genentech USA, INC. | $178.37 | 2023-2024 | Phesgo, Venclexta, Tecentriq |
| Puma Biotechnology, INC. | $176.48 | 2022-2024 | Nerlynx |
| Gilead Sciences, INC. | $174.63 | 2022-2024 | |
| Pharmaessentia USA Corporation | $170.84 | 2022-2024 | Besremi |
| Rigel Pharmaceuticals, INC. | $162.85 | 2022-2024 | Tavalisse, Rezlidhia |
| Sobi, INC | $154.19 | 2022-2024 | |
| Kite Pharma, INC. | $149.32 | 2022-2023 | Yescarta |
| Morphosys, US INC. | $148.69 | 2021-2024 | Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $137.92 | 2021-2023 | Imbruvica |
| Emd Serono, INC. | $135.01 | 2021-2024 | Bavencio |
| Mirati Therapeutics, INC. | $129.63 | 2023 | Krazati |
| Amgen INC. | $124.82 | 2022-2023 | Lumakras, Kyprolis |
| Alexion Pharmaceuticals, INC. | $122.37 | 2022-2024 | Ultomiris |
| Blueprint Medicines Corporation | $121.44 | 2022-2024 | Ayvakit |
| Seagen INC. | $105.22 | 2021-2023 | Adcetris, Tukysa |
| Eusa Pharma (US) LLC | $90.34 | 2022 | |
| Array Biopharma INC | $82.22 | 2022-2024 | Mektovi, Tukysa, Braftovi |
| Adaptive Biotechnologies Corporation | $82.05 | 2023-2024 | Clonoseq |
| Sanofi-Aventis U.S. LLC | $77.99 | 2022 | |
| Springworks Therapeutics, INC. | $72.67 | 2024 | Ogsiveo |
| Tersera Therapeutics LLC | $65.56 | 2022-2023 | Xermelo |
| Deciphera Pharmaceuticals INC. | $56.71 | 2023-2024 | Qinlock |
| Ge Healthcare | $54.27 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $51.39 | 2023-2024 | Fotivda |
| Genmab U.S., INC. | $50.35 | 2023-2024 | Epkinly |
| Immunogen, INC. | $48.09 | 2023-2024 | Elahere, Elahere |
| G1 Therapeutics, INC. | $42.13 | 2022-2023 | Cosela |
| Novocure INC. | $28.83 | 2024 | Optune |
| Ipsen Biopharmaceuticals, INC | $22.61 | 2024 | Somatuline Depot, Onivyde |
| Progenics Pharmaceuticals, INC. | $22.48 | 2022 | |
| Sanofi Pasteur INC. | $20.41 | 2022 | |
| Agios Pharmaceuticals, INC. | $19.79 | 2023 | Pyrukynd |
| Sun Pharmaceutical Industries INC. | $19.76 | 2024 | |
| Myovant Sciences INC. | $18.82 | 2022 | |
| Coherus Oncology, INC. | $18.62 | 2024 | |
| Stemline Therapeutics INC. | $17.77 | 2023 | Orserdu |
| Mylan Institutional INC. | $16.99 | 2022 | |
| Kaleo, INC. | $14.58 | 2024 | Auvi-Q |
| Emmaus Medical, INC. | $13.92 | 2023 | Endari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.